Arcus director granted RSUs and options
Arcus Biosciences director Andrew J. Perlman received new equity awards as part of his compensation.
Rhea-AI Filing Summary
Arcus Biosciences director Andrew J. Perlman received new equity awards as part of his compensation. He was granted 5,700 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and will fully vest if the company undergoes a change in control. Following this grant, he holds 48,325 Common Shares directly. Perlman also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and expiring on June 10, 2036, with full vesting upon a change in control. These awards are compensation-related grants rather than open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,600 shares
Grant/Award
2 txns
Insider
PERLMAN ANDREW J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,900 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,700 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,900 contracts (Direct);
Common Stock — 48,325 shares (Direct)
Footnotes (2)
- F1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
- F2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Key Figures
RSU grant size: 5,700 shares
Shares held after RSU grant: 48,325 shares
Stock option grant size: 16,900 shares
+3 more
6 metrics
RSU grant size
5,700 shares
Restricted stock units granted on June 11, 2026
Shares held after RSU grant
48,325 shares
Common Stock directly owned after transaction
Stock option grant size
16,900 shares
Stock option (right to buy) granted June 11, 2026
Option exercise price
$23.30 per share
Exercise price for 16,900-share stock option
Equity vesting date
June 11, 2027
Latest vesting date for RSUs and stock option, or earlier at next annual meeting
Option expiration
June 10, 2036
Expiration date of stock option grant
Key Terms
restricted stock units, change in control, stock option, exercise price, +1 more
5 terms
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "23.3000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Arcus Biosciences (RCUS) director Andrew Perlman report on this Form 4?
Andrew J. Perlman reported receiving new equity compensation awards. He was granted 5,700 restricted stock units and a stock option for 16,900 shares of Arcus Biosciences Common Stock, both vesting based on time and the company’s next annual stockholder meeting.
What are the terms of Andrew Perlman’s new stock option in Arcus Biosciences (RCUS)?
Andrew J. Perlman received a stock option covering 16,900 shares at an exercise price of $23.30 per share. The option vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting and expires on June 10, 2036.
When do Andrew Perlman’s new RSUs in Arcus Biosciences (RCUS) vest?
The 5,700 restricted stock units vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders. This means vesting could occur sooner if the company holds its next annual stockholder meeting before June 11, 2027.
How does a change in control affect Andrew Perlman’s Arcus Biosciences (RCUS) equity awards?
Both the restricted stock units and the stock option become fully vested if Arcus Biosciences undergoes a change in control. This acceleration provision means all 5,700 RSUs and the full 16,900-share option would vest immediately upon such a corporate event.
Are these Arcus Biosciences (RCUS) Form 4 transactions open-market buys or sells?
No. The Form 4 shows compensation-related awards, not open-market trades. Andrew J. Perlman acquired 5,700 restricted stock units and a 16,900-share stock option as grants, with no purchase price paid for the RSUs and a fixed exercise price for the option.
AI-generated analysis. How Rhea-AI works. Not financial advice.
